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Introduction
Over the past decade, Trichosporon spp. have been recog-
nized as opportunistic pathogens capable of causing inva-
sive infections, especially in immunosuppressed patients.1 
Infection with Trichosporon spp. has been associated with 
a high mortality rate in a retrospective study.2 These path-
ogens have rarely been reported to cause nosocomial 
infections in the literature.3 Here, we report the case of a 
nongranulocytopenic patient with nosocomial fungemia 
caused by Trichosporon asahii (formerly known as T. beigelii).
Case Report
A 53-year-old female was admitted to our hospital with a 
2-day history of lower back soreness and shortness of 
breath. She had also had 17-year history of paroxysmal 
nocturnal hemoglobinuria and anemia. Frequent blood 
transfusions resulted in secondary hemochromatosis and 
chronic renal insufficiency. A prior renal biopsy showed 
tubular deposition of hemosiderin. On admission, she 
appeared pale and dyspneic with a blood pressure of 
95/41 mmHg, a heart rate of 118 beats/min and a respira-
tory rate of 28 breaths/min. Physical examination showed 
ecchymoses and pitting edema in the lower extremities. 
The white cell count was 7,500/mm3 (96% neutrophils); 
hemoglobin was 9.7 g/dL; and hematocrit was 27.7%. 
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Blood biochemistry revealed ferritin, blood urea nitrogen, 
and creatinine values of 14,135 ng/mL, 263 mg/dL, and 
13.3 mg/dL, respectively. Arterial-blood gas analysis showed 
severe metabolic acidosis with a pH of 7.05 and a HCO3 
content of 3.1 mmol/L. Because both the blood and urine 
cultures revealed Klebsiella pneumonia infection, the patient 
initially received intravenous imipenem/cilastatin ther-
apy. She also received continuous venovenous hemodialy-
sis for severe azotemia and metabolic acidosis. Two sets of 
blood cultures collected on hospital day 9 showed growth 
of T. asahii, which was identified by use of the Vitek 2 YST 
yeast identification kit (Vitek 2 YST, Biomèrieux, Durham, 
NC, USA). Antifungal susceptibility testing, which was 
performed using the microbroth dilution technique in 
accordance with the guidelines of the Clinical and 
Laboratory Standards Institute,4 showed the following 
minimum inhibitory concentrations (susceptibility break-
points): amphotericin B, 0.5 mg/L (≤ 1); fluconazole, 4 mg/L 
(≤ 8); and voriconazole, 0.125 mg/L (≤ 1). The patient then 
received combination antifungal therapy with amphoter-
icin B deoxycholate (0.4 mg/kg/day, intravenously) and 
voriconazole (200 mg twice daily, orally) for 14 days. How-
ever, the patient eventually died from ventilator-associated 
pneumonia with tension pneumothorax 30 days after 
admission (or day 14 after the start of antifungal therapy). 
Blood cultures showed no fungemia at time of death.
Discussion
In the past 3 decades, the non-Candida yeast Trichosporon 
spp. have been increasingly recognized as opportunistic 
pathogens capable of causing invasive infections, espe-
cially in immunosuppressed patients.1 Guého et al de-
scribed human colonization with Trichosporon spp.5 The 
gastrointestinal tract, skin, and mucosal surfaces have 
been reported as the sites of colonization, and Trichosporon 
spp. have also been detected in stool, central venous cath-
eter, sputum, and hair.3
Thirty-eight Trichosporon spp. have been described in 
the current literature, and among these, eight are consid-
ered as potential human pathogens: T. asahii, T. asteroides, 
T. cutaneum, T. inkin, T. mucoides, T. ovoides, T. domesticum, 
and T. montevideense.6 Invasive Trichosporon infections are 
usually preceded by respiratory or gastrointestinal tract 
colonization, and are commonly associated with the use 
of central venous catheters.6 More recently, T. asahii and 
T. mucoides have emerged as major opportunistic patho-
gens responsible for invasive infections in immunosup-
pressed patients, and T. asahii has been described as the 
most frequently isolated species.5,6
Trichosporon spp. are characterized by their ability to 
form hyphae, pseudohyphae, arthroconidia and blasto-
conidia.6,7 Trichosporon spp. grow on ordinary Sabouraud-
dextrose agar as yeast with cream-colored cerebriform 
colonies.6 Culture identification can be confused with 
Candida spp. morphologically. Furthermore, invasive tri-
chosporonosis is difficult to differentiate histologically 
from invasive candidiasis, making definitive diagnosis 
more problematic.7,8 The presence of arthroconidia is the 
major microscopic feature that differentiates Trichosporon 
from Candida.2,7 In addition, the Trichosporon spp. are mor-
phologically similar to Cryptococcus, and the cell wall anti-
gen of Trichosporon spp. cross-reacts with the capsular 
polysaccharide of Cryptococcus neoformans; therefore the 
assay for the cryptococcal polysaccharide antigen may be 
positive in patients with trichosporonosis.9
There has been a considerable increase in the incidence 
of the invasive Trichosporon infection over the past 2 dec-
ades. Invasive infections are more common in patients 
with hematological malignancies.2 A shift to a predomi-
nance of catheter-related fungemia, without evidence of 
organ involvement, has been reported.10 The proposed 
explanation for this change is the increased use of central 
venous catheters and the widespread use of fluconazole 
prophylaxis. Wolf et al reported six nongranulocytopenic 
patients with invasive Trichosporon infection, in whom 
the isolates of T. asahii shared a similar phenotype and 
genotype, thereby suggesting a common nosocomial ori-
gin.3 In a recent review of the literature, Trichosporon 
fungemia was found to occur in 74% of all reported 
Trichosporon spp. infections; 50% of the cases were classi-
fied as disseminated, 16% of the cases had disease 
restricted to the lung, and 3.2% had focal hepatosplenic 
involvement.2 Although Trichosporon spp. have most often 
been implicated in invasive infections in immunosup-
pressed hosts, trichosporonosis in immunocompetent 
patients has rarely been reported.11
Profound granulocytopenia in patients with hemato-
logical malignancies has been reported as the most com-
mon risk factor for T. asahii fungemia. Other reported 
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predisposing factors include organ transplantation, exten-
sive burns, human immunodeficiency virus infection, 
corticosteroid therapy, prosthetic valve surgery, and peri-
toneal dialysis.3,12 Hemochromatosis is a separate risk fac-
tor for trichosporonosis.12 Two potential mechanisms 
have been described that increase the risk of fungal infec-
tion. First, iron serves as a nutrient for fungal growth, and 
is an important cofactor for enzymes involved in many 
basic cellular functions.13 Trichosporon grows rapidly 
in vitro in iron-supplemented media, and iron overload 
has been implicated as a factor in invasive Trichosporon 
infections.12 Second, an environment free of excess iron is 
required for the effective innate and acquired immune 
responses.14 Iron overload decreases T-cell antifungal immu-
nity, natural killer cell activity, and the phagocytic capacity 
of neutrophils and monocytes, thereby greatly increasing 
the possibility of invasive fungal infections.15,16
Although there have been many advances in antifun-
gal treatment of invasive fungal infections,17 the optimal 
therapy for trichosporonosis has yet to be identified. The 
new triazole voriconazole, alone or in combination, is 
probably the drug of choice for this infection, especially 
in a granulocytopenic patient.18,19 In patients who cannot 
be treated with voriconazole because of its side effects, 
amphotericin B, flucytosine, fluconazole, and itracona-
zole might be alternative antifungals,2 although multi-
drug resistance to these agents leading to treatment failure 
has been reported.3 Other new triazoles, namely, posaco-
nazole and ravuconazole, have also shown potent in vitro 
activity against isolates of T. asahii and other Trichosporon 
species.20 Reportedly, echinocandins have low activity 
against Trichosporon spp. and are not recommended for 
the treatment of trichosporonosis.17,21 The prognosis of 
invasive trichosporonosis has been dismal because the 
crude mortality rate is as high as 77% in published cases.3 
The poor results of treatment are mostly due to the 
advanced nature of the underlying illness.
In conclusion, T. asahii causes life-threatening infec-
tions, particularly in granulocytopenic patients. It is 
important to consider that emerging Trichosporon spp. 
infections are usually difficult to diagnose, are refractory 
to conventional antifungal agents, and are associated 
with a high mortality rate.2,6 Early diagnosis is crucial 
for successful therapy. Clinicians should be aware that 
Trichos poron fungemia might develop in patients with 
secondary hemochromatosis. Early detection and accu-
rate identification of this unusual pathogen are necessary 
to provide specific and timely antifungal therapy, and 
offer the patient a better chance of survival.
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